The OrganOx metra device was recently featured in use for a pioneering clinical trial (VITTAL) by the liver transplant team at the Queen Elizabeth II Hospital, Birmingham, UK. This pioneering study team is placing livers declined for transplant by all UK liver transplant centres on the OrganOx metra device, assessing their quality, and if deemed viable, transplanting them. Watch the documentary on BBC iPlayer (only available within the UK) HERE.
OrganOx is pleased to share the recent interview with co-founder Professor Constantin Coussios in The Economist. The metra® device normothermic liver perfusion technology was discussed, along with exciting plans for the future. Read more HERE
OrganOx, a leader in the field of organ preservation, has signed a 5 year agreement with Dismeval to distribute the OrganOx metra in Spain.
" We are delighted to have signed up Dismeval s.l to ensure the OrganOx metra is adopted in Spain. In terms of organ donation rates Spain leads the rest of the world, very much helped by the opt-out policy which has been in place since 1979. We have been impressed with Dismeval's track record over many years in driving other innovative surgical products into the Spanish market. With Dismeval as our partner in Spain we look forward to seeing the positive impact of our technology benefiting all involved in liver transplantation. " said Craig Marshall, CEO of OrganOx Limited.
"We recognise the potential of the OrganOx metra to further improve the utilisation of deceased donor livers in Spain. We anticipate first sales into leading Spanish liver transplant hospitals centres in Q4 of 2017" said Salvador Forés, General Manager of Dismeval s.l.
OrganOx is pleased to announce support of a local and very relevant charity, the Oxford Transplant Foundation. The mission of this charity is to further the science and practice of transplantation, and to provide support for education and training in transplantation, over and above that provided by the University of Oxford and National Health Service.
Learn more about the foundation HERE.
OrganOx is pleased to announce the appointment of Craig Marshall as CEO of OrganOx with effect from 1 January 2017. Craig joins OrganOx from Siemens Magnet Technology in Eynsham where he was the Managing Director since 2010, with a turnover in excess of £150m and employing over 400 people. Craig will take over as CEO from Dr Les Russell who is moving to the position of Chairman.
“I am delighted to be able to take up the role of CEO of OrganOx at such an exciting time as the company transitions to full commercial activities. We have an outstanding team which has developed the world leading product for liver preservation, the OrganOx metra which is transforming liver transplantation around the globe and saving more lives by enabling the transplantation of more organs. I look forward to leading OrganOx to even greater success in the future by ensuring our proprietary technology is adopted by transplant centres in Europe, America and beyond.”
New Chairman Dr Les Russell added
“On behalf of our company and investors, it is my pleasure to welcome Craig to the role of CEO. It is a tribute to the team and strength of the company that we are able to recruit such a talented and high calibre individual as Craig. During his time at Siemens, Craig led his business to become a role model for other design and manufacturing businesses, picking up the coveted Factory of the Year award in 2015. I look forward to working with Craig as we drive the company forward on its mission to improve the supply and quality of organs for transplantation worldwide.”